Design, synthesis, and multi-target evaluation of 4-phenyl quinoline-8-sulfonate thiosemicarbazones as potential anti-Alzheimer agents Authors: Rahma Saeed, Hafiza Zara Tariq, Aiysha Althobaiti, Nastaran Sadeghian, Parham Taslimi, Mariya Al-Rashida, Talha Islam, Hamdy Khamees Thabet, Hina Aftab, Halil Şenol, Mubashir Ameen, Jing Li, Zahid Shafiq Published: 2025 ABSTRACT Alzheimer’s disease (AD) is a progressive neurodegenerative disorder marked by cognitive and memory decline. A novel series of 4-phenyl-quinoline-8-sulfonate-based thiosemicarbazones 5(a–r) were synthesized, characterized by some spectroscopic techniques and evaluated for their potential as anti-Alzheimer agents. Among them, compound 5c, bearing an o-fluoro phenyl group, showed multi-target inhibition with an IC₅₀ values of 78.07 ± 3.14 µM acetylcholinesterase (AChE), 22.63 ± 2.81 µM butyrylcholinesterase (BChE) and 0.84 ± 0.01 µM monoamine oxidase A (MAO-A), showing higher inhibitory potential than the reference clorgyline with IC₅₀ value 66.20 ± 4.01 µM. Other compounds, such as 5e, 5 g, 5b and 5q also exhibited significant inhibition across targets. Molecular docking confirmed strong binding interactions, particularly with the catalytic sites of AChE, BChE and MAO-A. These findings highlight 5c as a promising lead for multi-targeted AD therapy.Supplementary InformationThe online version contains supplementary material available at 10.1038/s41598-025-32012-y. Introduction Alzheimer’s disease (AD) is a long-term neurological illness characterized by the steady deterioration of neurons, especially within the cholinergic system, and causing memory impairment, confusion, cognitive decline, and difficulty in reasoning and decision-making1–3. (AD) represents the principal etiology underlying dementia, contributing to approximately 50–75% of all diagnosed cases4,5. According to global health authorities, more than 55 million individuals worldwide are estimated to suffer from this chronic condition6. In (AD), several harmful changes take place in the brain. One of the main features is the formation of β-amyloid plaques, which are clumps of protein pieces called amyloid-β. These plaques build up between nerve cells and disturb their normal activity, causing damage to brain cells7,8. Another important problem is the presence of neurofibrillary tangles (NFTs) inside the nerve cells. These tangles are made from a protein called tau, which becomes faulty and gathers inside the cells, blocking the transport system and leading to cell death9. As the disease progresses, there is a gradual degeneration of nerve cells and their connections, especially in the hippocampus and cerebral cortex, which are important areas for memory and thinking10. A major part of this damage involves the cholinergic system, which uses a chemical messenger called acetylcholine (ACh) to help with memory and learning. In Alzheimer’s patients, cholinergic neurons get damaged, and the levels of ACh drop11. Acetylcholinesterase (AChE) is an important enzyme that breaks down the neurotransmitter ACh, which helps with memory and learning. In (AD), the activity of AChE is frequently elevated in the regions surrounding amyloid plaques and neurofibrillary tangles, leading to a faster breakdown of acetylcholine and worsening memory loss12. Another related enzyme is butyrylcholinesterase (BChE). Although BChE plays a smaller role in a healthy brain, its activity increases in the later stages of Alzheimer’s, when AChE levels decline. BChE becomes the primary enzyme breaking down ACh at this stage, contributing further to cognitive problems13. Monoamine oxidases (MAOs) break down neurotransmitters like dopamine and serotonin, producing harmful reactive oxygen species (ROS) as by-products. Increased MAO activity in (AD) leads to oxidative stress, and inhibiting these enzymes may help to protect nerve cells14. Due to the involvement of numerous targets in the (AD) network, multi-target-directed ligands (MTDLs) are considered a potential strategy for effective treatment15. By blocking MAOs, AChE and BChE, the levels of dopamine and cholinergic neurotransmitters in the brain can increase. This helps to protect brain cells by reducing harmful oxidative stress and improving memory and thinking abilities16. Cholinesterase inhibitors work by raising ACh concentrations at synapses in the brain and are among the limited drug treatments shown to be effective for managing (AD) dementia. This demonstrates the importance of the cholinergic system as a key target for treatment11. Plant extracts have shown therapeutic and preventive effects against Alzheimer’s disease (AD) by reducing inflammation and oxidative stress17,18. In another study, Apelin is reported to show neuroprotective effects by suppressing inflammation and reduced serum apelin-13 levels in AD highlighting its potential as a therapeutic target19. Thiosemicarbazones are a versatile class of compounds known for a wide range of pharmacological activities including antifungal, anticancer20,21, antiviral antimicrobial, and antiparasitic activities22,23. More recently, they have shown promise in treating neurodegenerative disorders due to their ability to inhibit AChE and BChE, thereby enhancing acetylcholine levels and supporting cognitive function24–26. At present, a variety of medications are used to treat (AD), such as rivastigmine, donepezil, memantine, galantamine and aducanumab27–29. Recent studies have highlighted thiosemicarbazone derivatives as promising multi-target agents for (AD), owing to their inhibitory effects on AChE, BChE and MAOs, along with notable antioxidant and neuroprotective properties Fig. 1. Heterocyclic derivatives serve as valuable scaffolds for developing potential enzyme inhibitors against Alzheimer’s disease (AD)30,31. Pharmacophore hybridization has been reported to combines multiple pharmacophoric features into one molecule to improve binding and efficacy32. Although thiosemicarbazones and quinoline-based derivatives have been extensively investigated for their biological potential1,17,33, the introduction of a 4-phenyl-8-quinoline sulfonyl moiety into thiosemicarbazones have not yet been explored. This novel structural modification is anticipated to improve binding infinity, selectivity and biological activity. Accordingly, the present study reports the synthesis of 4-phenyl-8-quinoline sulfonyl based thiosemicarbazones and evaluates their activity against key Alzheimer’s related enzymes34–36. Fig. 1Reported thiosemicarbazones as potential anti-Alzheimer agents34–36. Reported thiosemicarbazones as potential anti-Alzheimer agents34–36. Result and discussion Chemistry 4-Phenyl-quinoline-8-sulfonate based thiosemicarbazones 5(a–r) were efficiently synthesized as depicted in Fig. 2. The synthesis involved two steps. Initially, 4-formylphenyl quinoline-8-sulfonate (3) was obtained by the reaction of 4-hydroxybenzaldehyde with quinoline-8-sulfonyl chloride in dimethylformamide, in the presence of triethylamine. In the next step, equimolar amounts of compound 3 and the corresponding thiosemicarbazides 4(a–r) were refluxed in methanol, with acetic acid facilitating the reaction to produce the proposed series of thiosemicarbazone derivatives 5(a–r). The structure of the synthesized thiosemicarbazone derivatives 5(a–r) was confirmed using ¹H and ¹³C NMR spectroscopy. In the ¹H NMR spectra, characteristic signals were observed for the NH–C = S group as singlets within δ 11.43–12.09 ppm, while the NH–N = C moiety resonated in the range of δ 9.23–10.17 ppm. A distinct singlet corresponding to the azomethine proton (HC = N) appeared between δ 7.96–8.08 ppm, indicating successful condensation between the aldehyde and thiosemicarbazide. The ¹³C NMR data further corroborated the formation of the desired structures. Fig. 2Synthetic Route of 4-phenyl-quinoline-8-sulfonate based thiosemicarbazones. Synthetic Route of 4-phenyl-quinoline-8-sulfonate based thiosemicarbazones. Biological activity Structure activity relationship (SAR) Thiosemicarbazone derivatives 5(a–r), derived from the 4-phenyl-quinoline-8-sulfonate scaffold, were evaluated for their inhibitory activity against AChE, BChE and MAO-A using established protocols. The inhibitory effects are depicted in Table 1. The study focus on how R-groups variations in the thiosemicarbazides moiety influence enzyme inhibition. The results demonstrate that R-groups modifications play a crucial role in enhancing bioactivity by influencing enzyme-ligand interactions. Acetylcholinesterase (AChE) inhibition In comparison with the reference drug galantamine (IC₅₀ = 99.28 µM), several compounds from the 4-phenyl-quinoline-8-sulfonate-based thiosemicarbazone series 5(a–r) exhibited superior inhibitory effects on acetylcholinesterase, exhibiting IC₅₀ values between 75.05 and over 100 µM. The structure–activity relationship was examined by varying the R substituent on the thiosemicarbazide framework, and the findings suggest that the nature and position of substituents have a significant influence on the inhibitory potential. Among the entire series, compound 5 g, incorporating a 2,3-dichlorophenyl moiety, emerged as the most potent AChE inhibitor, displaying an IC₅₀ of 75.05 µM and a Ki of 69.11 µM, indicating a strong affinity for the enzyme. The presence of two electron-withdrawing chlorine atoms at adjacent positions likely enhances binding via improved hydrophobic interactions or a more favorable conformation. This suggests that multiple substitutions, particularly at ortho- and meta- positions, can significantly enhance inhibitory efficiency. Similarly, compound 5c with a 2-fluorophenyl group demonstrated high potency (IC₅₀ = 78.07 µM; Ki = 49.33 µM), indicating that ortho-substitution with small electronegative atoms like fluorine may support better fitting within the AChE active site. This beneficial effect seems less pronounced when the substituent is at the para- position, as seen in 5e (4-fluorophenyl), which showed slightly lower activity (IC₅₀ = 80.15 µM), though still superior to galantamine. Compounds with non-halogen ortho- or para- substituted phenyl rings, such as 5a (unsubstituted phenyl), 5n (2-methylphenyl), and 5o (sec-butyl), also showed moderate activity with IC₅₀ values of 85.36 µM, 86.15 µM, and 81.67 µM, respectively. These findings suggest that a hydrophobic or slightly bulky group can support enzyme binding, but the nature and position of the substituent play a critical role. In contrast, 5b (2-chlorophenyl) exhibited an IC₅₀ of 92.24 ± 1.62 µM and a Ki of 64.62 ± 6.24 µM, while 5k (3-methoxyphenyl) showed similar activity with an IC₅₀ of 92.09 ± 3.27 µM and a Ki of 89.04 ± 7.33 µM. This noticeable reduction in potency suggests that substitution at the meta position or the presence of bulky polar groups like methoxy may not favor optimal interactions within the AChE active site. Likewise, 5 h (2,6-dimethylphenyl) recorded an IC₅₀ of 92.92 ± 4.04 µM and a Ki of 82.22 ± 7.40 µM, and 5q (4-fluorobenzyl) displayed an IC₅₀ of 93.07 ± 7.68 µM with a Ki of 88.14 ± 11.58 µM. These findings suggest that steric hindrance from multiple ortho-substituents (as in 5 h) or the increased flexibility of benzylic linkers (as in 5q) likely compromises the compounds’ ability to bind efficiently to AChE. Further weakening of activity was observed in 5f (4-chlorobenzyl, IC₅₀ = 99.63 ± 4.20 µM), 5i (4-bromophenyl, IC₅₀ = 98.44 ± 3.11 µM), and 5p (4-chlorophenyl, IC₅₀ = 98.41 ± 4.34 µM). These results suggest that para-halogenation alone, especially in the absence of other supportive substituents or optimal ring orientation, is insufficient to confer strong AChE inhibition. The least active compounds, with IC₅₀ values exceeding 100 µM, include 5d (n-cyclohexyl), 5j (benzyl), 5 L (methyl), 5 m (2,4-dimethylphenyl), and 5r (hydrogen). These derivatives showed negligible inhibition, suggesting that non-aromatic or overly simple aliphatic groups (as in 5d, 5 L, 5r), or overly bulky substituents (as in 5 m), result in poor accommodation within the AChE active site. The complete loss of activity in 5r underscores the importance of having a substantial substituent at the R position to support binding interactions. Butyrylcholinesterase (BChE) inhibition Among the series, compound 5c (2-fluorophenyl) exhibited the strongest inhibition of BChE, exhibiting an IC₅₀ value of 22.63 µM and Ki of 12.34 µM, indicating a favorable interaction between the fluorine substituent at the ortho-position and the enzyme’s active site. Likewise, compound 5 g (2,3-dichlorophenyl) also demonstrated potent inhibition (IC₅₀ = 24.06 µM; Ki = 20.82 µM), supporting the beneficial role of multiple electron-withdrawing groups in enhancing binding affinity. Compound 5b (2-chlorophenyl) followed closely with an IC₅₀ of 28.37 µM, and a relatively low Ki of 18.50 µM, reaffirming the importance of ortho-chloro substitution. A similar trend was observed in compound 5e (4-fluorophenyl), which also showed promising activity (IC₅₀ = 34.16 µM; Ki = 19.27 µM), although less effective than its ortho-substituted counterparts, suggesting positional sensitivity of halogen atoms. Moderate BChE inhibition was noted in 5f (4-chlorobenzyl, IC₅₀ = 39.42 µM) and 5 h (2,6-dimethylphenyl, IC₅₀ = 48.13 µM), indicating that either benzylic flexibility or steric hindrance from dual ortho-methyl groups may hinder optimal binding. Similarly, 5q (4-fluorobenzyl) also fell in this mid-range (IC₅₀ = 49.52 µM), consistent with the idea that benzylic substitution reduces rigidity and limits interaction strength. Slightly weaker activity was recorded for 5i (4-bromophenyl, IC₅₀ = 53.22 µM) and 5d (n-cyclohexyl, IC₅₀ = 56.09 µM), suggesting that bulky non-aromatic or heavy halogen groups are less conducive to effective BChE inhibition. Other analogues in this range included 5j (benzyl, IC₅₀ = 57.09 µM) and 5p (4-chlorophenyl, IC₅₀ = 56.33 µM), both showing moderate affinity. Further reduction in potency was evident in 5k (3-methoxyphenyl, IC₅₀ = 62.47 µM) and 5 L (methyl, IC₅₀ = 66.15 µM), suggesting that small electron-donating groups or lack of aromatic bulk do not sufficiently stabilize the ligand–enzyme complex. This trend continued with 5 m (2,4-dimethylphenyl, IC₅₀ = 70.92 µM) and 5n (2-methylphenyl, IC₅₀ = 75.57 µM), indicating that methylation—particularly at ortho or para positions—may have limited benefit. Compound 5o (sec-butyl) exhibited weak activity (IC₅₀ = 81.26 µM), nearly similar to galantamine (IC₅₀ = 80.27 µM), highlighting the importance of aromaticity in enhancing inhibition. The least active compound was 5r (hydrogen), with an IC₅₀ of 97.01 µM and Ki of 72.64 µM, reaffirming that the absence of a substituent leads to poor BChE affinity. Monoamine oxidase-A (MAO-A) inhibition The evaluation of MAO-A inhibitory activity across the thiosemicarbazone series revealed that several analogues showed remarkable potency, with IC₅₀ values significantly lower than the reference inhibitor, clorgyline (IC₅₀ = 66.20 µM). The compound 5c (2-fluorophenyl) displayed the highest potency with an IC₅₀ of just 0.84 µM, suggesting that a small electronegative group at the ortho-position strongly enhances MAO-A affinity. Similarly, 5e (4-fluorophenyl) and 5q (4-fluorobenzyl) also exhibited high potency, with IC₅₀ of 1.02 µM and 1.09 µM, respectively. These results indicate that fluorine, whether at the ortho- or para-position on phenyl or benzyl rings, contributes significantly to enzyme binding, likely via strong electronic effects and favorable positioning within the active site. Other compounds with excellent activity includes 5j (benzyl) and 5p (4-chlorophenyl), with IC₅₀ values of 1.93 µM and 2.77 µM, respectively. This suggests that non-substituted benzylic systems and para-halogenated aryl rings also support tight binding, possibly due to hydrophobic interactions within the enzyme cavity. Moderate inhibition was observed for 5 h (2,6-dimethylphenyl) and 5k (3-methoxyphenyl), with IC₅₀ of 4.07 µM and 4.05 µM, respectively. These results suggest that although steric hindrance from ortho- substituents or bulkier polar groups at meta- positions can be tolerated, they may reduce optimal binding efficiency. Compound 5a (phenyl) displayed moderate inhibition as well (IC₅₀ = 5.13 µM), serving as a reference to gauge the effect of substitutions. Introduction of electron-withdrawing groups like chlorine in 5f (4-chlorobenzyl, IC₅₀ = 6.25 µM) or larger hydrophobic substituents in 5d (n-cyclohexyl, IC₅₀ = 7.82 µM) and 5i (4-bromophenyl, IC₅₀ = 7.41 µM) led to reduced potency, possibly due to either steric effects or suboptimal interactions with the active site. Further reduction in activity was noted in 5b (2-chlorophenyl, IC₅₀ = 9.22 µM) and 5 g (2,3-dichlorophenyl, IC₅₀ = 9.36 µM), where multiple or unfavorably positioned halogens may interfere with proper binding geometry. Compounds with relatively weak MAO-A inhibition included 5 L (methyl, IC₅₀ = 6.72 µM), 5 m (2,4-dimethylphenyl, IC₅₀ = 11.62 µM), and 5o (sec-butyl, IC₅₀ = 11.47 µM), reflecting that smaller alkyl groups or bulky non-aromatic systems may not contribute positively to binding affinity. The least effective analogues were 5n (2-methylphenyl, IC₅₀ = 17.02 µM) and 5r (hydrogen, IC₅₀ = 17.56 µM), indicating that minimal or non-functional R-groups severely compromise interaction with MAO-A. Table 1SAR evaluation of compounds 5(a–r) targeting AChE, BChE, and MAO-A.CodeIC50 (µM)Ki (µM)AchEBChEMAO-AAChEBChE5a85.36 ± 2.0773.20 ± 1.075.13 ± 0.0758.04 ± 4.3843.76 ± 3.255b92.24 ± 1.6228.37 ± 0.549.22 ± 0.1864.62 ± 6.2418.50 ± 1.095c78.07 ± 3.1422.63 ± 2.810.84 ± 0.0149.33 ± 7.0712.34 ± 2.845d> 10056.09 ± 3.227.82 ± 0.20> 10035.93 ± 4.335e80.15 ± 3.4934.16 ± 3.071.02 ± 0.3559.07 ± 5.2919.27 ± 3.065f99.63 ± 4.2039.42 ± 4.376.25 ± 0.0174.68 ± 8.5226.03 ± 5.555 g75.05 ± 3.5224.06 ± 2.529.36 ± 0.5869.11 ± 5.0920.82 ± 3.205 h92.92 ± 4.0448.13 ± 4.614.07 ± 0.2682.22 ± 7.4027.15 ± 2.435i98.44 ± 3.1153.22 ± 5.077.41 ± 0.5196.37 ± 8.5931.30 ± 0.765j> 10057.09 ± 6.411.93 ± 0.02> 10037.62 ± 4.095k92.09 ± 3.2762.47 ± 7.224.05 ± 0.7389.04 ± 7.3340.01 ± 5.265 L> 10066.15 ± 4.016.72 ± 0.15> 10033.73 ± 6.485 m> 10070.92 ± 5.1011.62 ± 0.29> 10048.42 ± 4.315n86.15 ± 3.4475.57 ± 6.4117.02 ± 1.8176.09 ± 8.1853.19 ± 5.705o81.67 ± 6.2881.26 ± 4.0711.47 ± 0.3970.51 ± 7.2269.67 ± 3.825p98.41 ± 4.3456.33 ± 6.132.77 ± 0.5682.29 ± 6.7344.02 ± 4.535q93.07 ± 7.6849.52 ± 5.261.09 ± 0.0988.14 ± 11.5838.33 ± 6.945r> 10097.01 ± 6.5717.56 ± 0.33> 10072.64 ± 5.07Galantamine99.28 ± 3.1680.27 ± 3.09–94.09 ± 7.3364.06 ± 3.66Clorgyline––66.20 ± 4.01–– Table 1SAR evaluation of compounds 5(a–r) targeting AChE, BChE, and MAO-A.CodeIC50 (µM)Ki (µM)AchEBChEMAO-AAChEBChE5a85.36 ± 2.0773.20 ± 1.075.13 ± 0.0758.04 ± 4.3843.76 ± 3.255b92.24 ± 1.6228.37 ± 0.549.22 ± 0.1864.62 ± 6.2418.50 ± 1.095c78.07 ± 3.1422.63 ± 2.810.84 ± 0.0149.33 ± 7.0712.34 ± 2.845d> 10056.09 ± 3.227.82 ± 0.20> 10035.93 ± 4.335e80.15 ± 3.4934.16 ± 3.071.02 ± 0.3559.07 ± 5.2919.27 ± 3.065f99.63 ± 4.2039.42 ± 4.376.25 ± 0.0174.68 ± 8.5226.03 ± 5.555 g75.05 ± 3.5224.06 ± 2.529.36 ± 0.5869.11 ± 5.0920.82 ± 3.205 h92.92 ± 4.0448.13 ± 4.614.07 ± 0.2682.22 ± 7.4027.15 ± 2.435i98.44 ± 3.1153.22 ± 5.077.41 ± 0.5196.37 ± 8.5931.30 ± 0.765j> 10057.09 ± 6.411.93 ± 0.02> 10037.62 ± 4.095k92.09 ± 3.2762.47 ± 7.224.05 ± 0.7389.04 ± 7.3340.01 ± 5.265 L> 10066.15 ± 4.016.72 ± 0.15> 10033.73 ± 6.485 m> 10070.92 ± 5.1011.62 ± 0.29> 10048.42 ± 4.315n86.15 ± 3.4475.57 ± 6.4117.02 ± 1.8176.09 ± 8.1853.19 ± 5.705o81.67 ± 6.2881.26 ± 4.0711.47 ± 0.3970.51 ± 7.2269.67 ± 3.825p98.41 ± 4.3456.33 ± 6.132.77 ± 0.5682.29 ± 6.7344.02 ± 4.535q93.07 ± 7.6849.52 ± 5.261.09 ± 0.0988.14 ± 11.5838.33 ± 6.945r> 10097.01 ± 6.5717.56 ± 0.33> 10072.64 ± 5.07Galantamine99.28 ± 3.1680.27 ± 3.09–94.09 ± 7.3364.06 ± 3.66Clorgyline––66.20 ± 4.01–– SAR evaluation of compounds 5(a–r) targeting AChE, BChE, and MAO-A. The SAR study revealed that electron-withdrawing substituents, particularly ortho-fluorine and para-halogen groups, significantly enhance inhibition of AChE, BChE, and MAO-A. Compound 5c (2-fluorophenyl) consistently showed the highest potency across all three targets, highlighting the critical role of small, electronegative ortho-substituents in optimizing enzyme binding affinity Fig. 3. Fig. 3Illustration of structural diversity and the influence of chemical modifications on biological activity. Illustration of structural diversity and the influence of chemical modifications on biological activity. Molecular docking study Molecular docking of ache inhibitors Docking of all active inhibitors of AChE indicates that they bind in the same area of the active site as the co-crystallized inhibitor dihydrotanshinone I Fig. 4. Compounds 5c, 5e and 5 g had were most active AChE inhibitors and had similar activities (IC50 = 78.07 ± 3.14, 80.15 ± 3.49 and 75.05 ± 3.52 µM respectively). Hydrogen bonds were found in all three ligands, common amino acids interacting (hydrogen bond) with all three compounds were Ser293, Tyr124, and Tyr341. In addition to these, few unique interactions were also observed for each compound Fig. 5. For compound 5c, the sulfone group oxygen and NH group were making hydrogen bonds with Arg296 and Ser125 respectively. For compound 5e, the sulfone group oxygen and NH group were making hydrogen bonds with Ser293 and Ty124 respectively. Fig. 4Overlap of docked conformations of AChE inhibitors with the co-crystallized inhibitor dihydrotanshinone I (represented in black). Overlap of docked conformations of AChE inhibitors with the co-crystallized inhibitor dihydrotanshinone I (represented in black). For compound 5 g, the sulfone group oxygen was making a hydrogen bond with Ser293, while the sulfonate oxygen was making a hydrogen with Arg296; its NH groups were making hydrogen bonds with Tyr337. Halogen bonds were also observed for all three compounds with Gly121, Glu202 and Gly120 Table 1S. Fig. 5Binding site interactions of docked conformations of AChE inhibitors (A) 5c, (B) 5e and (C) 5 g indicating similar binding orientation and interactions. Binding site interactions of docked conformations of AChE inhibitors (A) 5c, (B) 5e and (C) 5 g indicating similar binding orientation and interactions. The hydrophobic pi-pi T-shaped and pi-pi stacked interactions with Trp86 and the halogen substituted phenyl ring were observed for all three compounds. One of the Cl in 5 g was additionally making a pi-alkyl interaction with Trp86. pi-Sulfur interactions were observed in 5e and 5 g but not in 5c. The quinoline ring in 5c and 5e was making a pi-sigma and a pi-alkyl interaction with Leu289, while for 5 g a pi-pi T-shaped interaction with Trp286 was observed. The quinoline ring in 5e was making pi-pi stacked and a pi-sigma interaction with Trp286, and a pi-pi T-shaped interaction with His287. Compound 5e showed the strongest pi-pi stacking pattern with Trp286, and halogen bonding with Glu202, not seen in others, hence was selected for MD simulation studies. The phenyl ring in the middle of the molecule was making pi-pi stacked interactions with Tyr341 (in 5c), Trp286 (in 5e) and a pi-alkyl with Val294 in 5 g Fig. 6. Fig. 6Summary of binding site interactions of AChE inhibitors 5c, 5e and 5 g. Summary of binding site interactions of AChE inhibitors 5c, 5e and 5 g. Molecular docking of BChE inhibitors All compounds were able to inhibit BChE, several compounds exhibited even better inhibition activity than the standard inhibitor. Compounds 5b, 5c and 5 g were most active inhibitors with quite similar IC50 values (28.37 ± 0.54, 22.63 ± 2.81 and 24.06 ± 2.52 µM respectively) and were therefore selected for detailed analysis of binding site interactions. Figures 7 and 8 shows overlap of docked conformations of these compounds, showing that they bind in the same area of the binding site as the co-crystallized inhibitor tacrine. Details of these interactions are given in Table 2S. Fig. 7Overlap of docked conformations of BChE inhibitors 5b, 5c and 5 g with the co-crystallized inhibitor tacrine (represented in black). Overlap of docked conformations of BChE inhibitors 5b, 5c and 5 g with the co-crystallized inhibitor tacrine (represented in black). Fig. 8Binding site interactions of docked conformations of BChE inhibitors (A) 5b, (B) 5c and (C) 5 g indicating similar binding orientation and interactions. Binding site interactions of docked conformations of BChE inhibitors (A) 5b, (B) 5c and (C) 5 g indicating similar binding orientation and interactions. The oxygen atoms of the sulfone group of 5b, 5c and 5 g were making hydrogen bonds with Gly116, Gly117, and Ala199, indicating interaction with these amino acids is important for enzyme inhibition Fig. 9. Asp70 was involved in hydrogen bonding with the NH groups of compounds 5b and 5 g. In compounds 5c and 5 g halogen bonds were observed with Pro285 and His438. Fig. 9Summary of binding site interactions of BChE inhibitors 5b, 5c and 5 g. Summary of binding site interactions of BChE inhibitors 5b, 5c and 5 g. The sulfur atom of the sulfone group in all three compounds was found to be making pi-sulfur bonds with aromatic residues His438 and Phe398, while the sulfur atom of the thiocarbonyl group in compounds 5b and 5 g was making pi-sulfur bond with Trp430, Tyr332 and Trp82. The quinoline ring in all compounds was making pi-pi T-shaped interactions with Phe329, Trp231, His438 and Trp82. The phenyl ring in the middle of the molecule was making intramolecular pi-pi stacked or pi-pi T-shaped interactions with either the quinoline ring or the other phenyl ring. The terminal phenyl ring in 5c and 5 g was making pi-pi stacked interaction with Tyr332, in compound 5 g a pi-pi T-shaped interaction additionally observed with Phe329. These trends are summarized in Fig. 8. Molecular docking studies of MAO A inhibitors The docking of compounds 5c, 5e and 5q with MAO A showed their orientation near the opening of the active site, covering its entrance Fig. 10, not interacting with the co-factor FAD, unlike the co-crystallized inhibitor harmine. The docking results for 5c, 5e, and 5q revealed both shared and distinct interactions with MAO A. Table 3S shows details of interactions with the binding site residues. Fig. 10Overlap of docked conformations of MAO A inhibitors 5c, 5e and 5q with the co-crystallized inhibitor harmine (represented in black) and FAD co-factor (in blue), (A) without surface representation, (B) with surface representation, (C) zoomed-in region showing inhibitors are oriented slightly outward, hindering/covering the opening of the binding site as compared to harmine which is snugged inside the active site. Overlap of docked conformations of MAO A inhibitors 5c, 5e and 5q with the co-crystallized inhibitor harmine (represented in black) and FAD co-factor (in blue), (A) without surface representation, (B) with surface representation, (C) zoomed-in region showing inhibitors are oriented slightly outward, hindering/covering the opening of the binding site as compared to harmine which is snugged inside the active site. Ala111 forms hydrogen bonds with the azomethine nitrogen (–C=N–) of 5c and 5e, while the NH groups of 5e and 5q were making hydrogen bonds with Thr211 and Phe208. The sulfone group oxygen atoms were making hydrogen bonds with Val115 and Gly110. Halogen bonds were observed in 5c and 5q with Thr211 and Tyr407. The terminal phenyl ring was making pi-alkyl interactions with Val210, Val93, Ala111 in 5e and with Leu337 and Ile180 in 5q. The sulfur atom of the sulfone group was making pi-sulfur interaction with Tyr121 and Tyr124 in 5c and 5e. The quinoline ring was making pi-pi T-shaped interactions with Tyr121, Trp116 in 5c and pi-alkyl interaction with Pro114 in 5c and 5e, and with Arg109 and Gly110 in 5q Fig. 11. Fig. 11Binding site interactions of docked conformations of MAO A Inhibitors (A) 5c, (B) 5e and (C) 5q. Binding site interactions of docked conformations of MAO A Inhibitors (A) 5c, (B) 5e and (C) 5q. The phenyl ring in the middle of the molecule was making pi-donor interaction with Phe112 in 5c and 5e; the same ring was also making pi-alkyl interaction with Ala119 in 5c and 5e, while for 5q Val93, Val210, Leu97 and Ala111 were making pi-alkyl interactions with the same phenyl ring Fig. 12. An amide pi stacked interaction was uniquely observed for 5q between this phenyl ring and Gly110. Fig. 12Summary of binding site interactions of MAO A inhibitors 5c, 5e and 5q (where, n = 0, 1). Summary of binding site interactions of MAO A inhibitors 5c, 5e and 5q (where, n = 0, 1). Molecular dynamic simulation Molecular dynamics (MD) simulations are essential tools for exploring the dynamic behaviour, structural flexibility, and stability of protein-ligand complexes at the atomic level, offering critical insights into drug discovery and design. In the present study, 100-nanosecond MD simulations were conducted to evaluate the dynamic stability and interaction patterns of three selected docked complexes: 5e–AChE, 5 g–BChE, and 5c–MAO-A. These complexes were chosen based on their favourable docking scores and binding interactions identified during molecular docking studies. The simulations were performed using Desmond software integrated with Schrödinger Maestro 2024.4, under NPT ensemble conditions at 300 K temperature and 1.01325 bar pressure. Each complex was analyzed in terms of root-mean-square deviation (RMSD), root-mean-square fluctuation (RMSF), secondary structure elements (SSE), protein-ligand contacts, and ligand torsion profiles to assess their conformational stability and binding consistency throughout the simulation. The results provided valuable insights into the structural stability and dynamic interaction mechanisms of the selected inhibitors with their respective enzyme targets. MD simulation studies of ache inhibitor The MD plot of 5e-AChE complex showed that the C-α RMSD of the protein increased from 1 to 2.4 Å during the first 39ns, after which it stabilized around 2.6 Å for the rest of the simulation. The ligand RMSD (Lig fit on Protein) fluctuated in the range 3.0 Å to 4.8 Å during the simulation and stabilized around 4.2 Å towards the end. The internal stability of 5e (Lig fit on Lig) showed only a slight increase during the initial 20 ns and remained stable between 1.5 Å and 2.0 Å throughout the simulation. The RMSF analysis of the protein showed that most residues showed fluctuations < 3.0 Å, except the C-terminal residues, indicating increased flexibility in this region. The ligand RMSF (Lig fit on Protein) demonstrated that most atoms of 5e fluctuated around 1.0 Å, with fluorobenzene moiety showing higher flexibility (2.2 Å). Secondary structure analysis (SSE) of the protein showed that 37.67% of the structure was composed of secondary structure elements, including 25.01% α-helices and 12.66% β-strands. Protein-Ligand interaction profile indicated highest interaction fraction by Phe 295 which comprised primarily of hydrogen bonds and water bridges. The sulfonate moiety of 5e maintained 91% hydrophobic interactions with Phe 295. Phe 338 and Trp 86 maintained 56% and 35% Pi-Pi stacking and hydrophobic interactions with phenyl and fluorobenzene moieties of 5e, respectively. Tyr 124 showed and maintained 30% hydrophobic interactions with nitrogen of thiosemicarbazone moiety. Torsional analysis showed that all rotatable bonds in 5e maintained relatively stable torsion angles Fig. 13. The molecular dynamics simulation results of 5e with AChE showed that the complex remained relatively stable during the whole 100ns simulation time as the protein RMSD value was exhibited below 3.0 Å during the whole simulation. Moreover, RMSD values of 5e, simulation trajectory, 5e’s ligand RMSF, and torsional profile analysis revealed that 5e maintained its conformation, orientation, and position of the docked pose with AChE during the whole simulation. Fig. 13MD simulation studies of complex of 5e with AChE for 100ns, (A) RMSD plot; (B) Protein RMSF graph; (C) Ligand RMSF graph and (D) protein ligand contacts. MD simulation studies of complex of 5e with AChE for 100ns, (A) RMSD plot; (B) Protein RMSF graph; (C) Ligand RMSF graph and (D) protein ligand contacts. Overall RMSD values suggested that complex attained equilibrium during the simulation Fig. 14. Fig. 14Ligand Protein Contacts, and Ligand Torsion Profile of 5e with AChE. Ligand Protein Contacts, and Ligand Torsion Profile of 5e with AChE. MD simulation studies of BChE inhibitor The MD plot of the 5 g-BChE complex showed that the C-α RMSD fluctuated in the narrow range of 1.25 Å to 2.25 Å during the whole simulation period and remained stabilized around 2.2 Å towards the end. In the 5 g RMSD graph, the Lig fit on Protein value remained fluctuating between 2.5 Å to 4.5 Å during the simulation and remained around 3.5 Å in the end. 5 g’s Lig fit on lig RMSD value, remained between 1.5 Å to 2.7 Å during the simulation and was around 2.2 Å near the end. The Root-mean-square fluctuation (RMSF) analysis of BChE showed that most residues showed fluctuations < 2.5 Å, except Val 377 (3.14 Å) and the C-terminal residues indicating increased mobility in the loop region. The ligand RMSF profile (Lig fit on Protein) showed that the majority of atoms in compound 5 g fluctuated below 2.0 Å, suggesting stable binding. However, the indole moiety of 5 g exhibited relatively higher atomic fluctuations, reaching up to 3.5 Å. Secondary Structure analysis of the protein revealed total SSE of 39.39%, comprising of α-helices (25.70%) and β-strands (13.69%). Protein ligand interaction profile revealed that Thr 120 exhibited highest interaction fraction (> 1.0) which consisted primarily of water-bridge-based interactions. Ligand-protein contacts showed that Trp 231 exhibits hydrophobic and Pi-Pi interactions with dichlorobenzene moiety at 43%. While Asn 68 showed polar interactions with indole moiety at 34%. Thr 120 and Gly 116 maintained water-mediated interactions with thiosemicarbazone moiety of 5 g. Torsional analysis demonstrated that all rotatable bonds in compound 5 g remained conformationally stable throughout the simulation, except for the bond connecting the indole group, which showed slightly increased torsional flexibility Fig. 15. Fig. 15MD simulation studies of complex of 5 g with BChE for 100ns, (A) RMSD plot; (B) Protein RMSF graph; (C) Ligand RMSF graph and (D) protein ligand contacts. MD simulation studies of complex of 5 g with BChE for 100ns, (A) RMSD plot; (B) Protein RMSF graph; (C) Ligand RMSF graph and (D) protein ligand contacts. The molecular dynamics simulation results of 5 g with BChE showed that the complex remained relatively stable during the whole 100ns simulation time as the protein RMSD value remained below 2.25 Å during the whole simulation. However, RMSD values of 5 g, simulation trajectory, 5 g ligand RMSF, and torsional profile analysis revealed that 5 g maintained its docked position, and orientation in the active site of the BChE, however, the dynamic movement was observed in the indole moiety of the compound, which was also corroborated by the trajectory analysis, ligand RMSF, and torsion profile analysis of 5 g. Overall, 5 g remained attached to BChE in the active site of the enzyme during the whole simulation period Fig. 16. Fig. 16Ligand Protein Contacts (left), and Ligand Torsion Profile (right) of 5 g with BChE. Ligand Protein Contacts (left), and Ligand Torsion Profile (right) of 5 g with BChE. MD simulation studies of MAO A inhibitor The MD plot of the 5c-MAO-A complex showed an increase in the C-α Protein RMSD from 1.2 Å to 5.07 Å in the first 13ns, after which the value kept fluctuated around 4.2 Å while raised around 4.8 Å towards the end. The 5c RMSD graph, showed fluctuation of Lig fit on Protein value between 2.0 Å to 4.5 Å, while remaining around 3.5 Å towards the end of the simulation. A stable ligand RMSD value of approximately 1.75 Å was maintained during most of the simulation. Protein RMSF profile indicated the majority of the protein residues fluctuated less than 2.5 Å, except Asp 343 (2.96 Å), Gly 344 (3.55 Å) and the C-terminal residues. residues involved in binding with ligand 5c demonstrated limited flexibility, with RMSF values under 2.5 Å. Ligand RMSF plot indicated that all ligand (5c) atoms fluctuated in a narrow range1.2 Å to 1.75 Å. Secondary Structure analysis of the protein revealed a total SSE content of 42.71%, comprising of α-helices (26.83%) and β-strands (15.88%). Protein-Ligand interaction profile showed that Thr 211 exhibited highest interaction fraction (> 0.8) primarily via water bridges and hydrogen bonds interactions highlighting its key role in ligand stabilization. Ligand-protein contacts reveal that Asn 125 made 70% polar interactions with the sulfonate moiety of 5c. Trp 128 and Phe 112 maintained hydrophobic and π-π stacking interactions with phenyl group at 63% & 45%, respectively. Thr 211 maintained polar interactions at 79% with nitrogen of thiosemicarbazone moiety of 5c. The torsional profile of compound 5c indicated minimal fluctuations across all rotatable bonds Fig. 17. Fig. 17MD simulation of 5c with MAO A for 100ns, (A) RMSD plot; (B) Protein RMSF graph; (C) Ligand RMSF graph and (D) protein ligand contacts. MD simulation of 5c with MAO A for 100ns, (A) RMSD plot; (B) Protein RMSF graph; (C) Ligand RMSF graph and (D) protein ligand contacts. The MD simulation of 5c with MAO-A revealed that despite RMSD values of protein around 4.8 Å, the complex maintained structural stability throughout the simulation period. Regardless that 5c is docked at the peripheral site, other than the active site of MAO-A. RMSD values of 5c, simulation trajectory, Ligand RMSF, and torsional profile analysis revealed that 5c displayed stable behavior and remained attached with MAO-A in stable docked conformation, position, and orientation during the whole simulation. Moreover, relatively lower RMSF values of MAO-A residues that made contact with 5c suggest that the interaction of 5c with MAO-A contributed towards the stability of the complex Fig. 18. Fig. 18Ligand Protein Contacts, and Ligand Torsion Profile of 5c with MAO A. Ligand Protein Contacts, and Ligand Torsion Profile of 5c with MAO A. Experimental General All starting materials, including 4-hydroxybenzaldehyde and triethylamine, were acquired from Sigma-Aldrich and employed directly in the reactions without undergoing additional purification steps. Solvents such as dimethylformamide (DMF), petroleum ether, ethyl acetate, methanol, and acetic acid were purchased from Merck and utilized without modification. Reaction monitoring was carried out through TLC analysis on aluminum-supported silica gel plates. NMR measurements for both ¹H and ¹³C were carried out at 25 °C using a Bruker Ascend spectrometer, operating at 400 MHz for protons and 101 MHz for carbon nuclei, with DMSO-d₆ as the solvent. All chemical shifts are given in ppm, while coupling constants (J) are reported in Hz alongside signal multiplicities. High-resolution mass spectrometry (HRMS) was carried out using electrospray ionization (ESI) on a Thermo Fisher Scientific Q Exactive™ Hybrid Quadrupole-Orbitrap™ instrument. HPLC analyses were performed on a waters e2695 system equipped with Empower 3 software, employing a 1:4 water-acetonitrile mobile phase at a flow rate of 1 mL/min. Peak detection was achieved with PDA detector (model 2998) set at 363 nm. General procedure for the synthesis of 4-formylphenyl quinoline-8-sulfonate (3) The synthesis of compound (3) was carried out according to previously reported method24,37. Briefly, 4-hydroxybenzaldehyde 0.41 g (3.36 mmol) was reacted with 0.477 mL (3.36 mmol) of triethylamine, using 10 mL of dimethylformamide (DMF) as solvent. The mixture was kept in an ice bath with stirring. After 15 min, equimolar amount of quinoline-8-sulfonyl chloride (3.36 mmol) was added dropwise. The reaction mixture was stirred for an additional 1 h, and completion was monitored using thin-layer chromatography (TLC). Upon completion, the mixture was poured into 50 ml of ice-cold water, resulting in the formation of a solid precipitate. The solid was collected by filtration, washed thoroughly with distilled water, and dried to yield the desired product in a good yield. FTIR (cm− 1) 1702 (C = O), 3054 (Ar. C-H). 1H NMR δ H (400 MHz, Chloroform-d) 9.90 (1 H, s), 9.20 (1 H, dd, J 4.3, 1.8), 8.40 (1 H, dd, J 7.4, 1.5), 8.29 (1 H, dd, J 8.4, 1.8), 8.14 (1 H, dd, J 8.2, 1.5), 7.83–7.70 (2 H, m), 7.66–7.54 (2 H, m), 7.31–7.19 (2 H, m). 13C NMR (101 MHz, CDCl3) δ 190.66, 154.21, 152.40, 143.90, 136.67, 135.67, 134.64, 134.06, 132.46, 131.18, 129.02, 125.26, 122.84, 122.74. General procedure for the synthesis of thiosemicarbazones 5(a-r) A solution of 4-formylphenyl quinoline-8-sulfonate (3) (0.1 g, 0.32 mmol) was prepared in 10 mL of methanol with the addition of a catalytic amount of acetic acid (2–3 drops). The mixture was heated under reflux at 70 °C until complete dissolution of the compound. Subsequently, an equimolar amount (0.32 mmol) of the appropriate thiosemicarbazide derivative 4(a–r) was added to the reaction mixture. Refluxing was continued for 7–8 h, and the reaction progress was monitored periodically by thin-layer chromatography (TLC) until complete consumption of the starting materials. After completion, the reaction mixture was allowed to cool to room temperature. The resulting solid was collected by filtration, washed thoroughly with methanol to remove impurities, and dried to obtain the final products 5(a-r). ( E )−4-{[2-(Phenylcarbamothioyl)hydrazono]methyl}phenyl quinoline-8-sulfonate (5a) Off-white solid. Yield: 63%. Mp: 164–166 °C. FTIR (cm− 1) 3217 (N-H), 3054 (Ar. C–H), 1524 (C=N), 1186 (C=S). 1H NMR (400 MHz, DMSO-d6) δ H 11.85 (1 H, s), 10.09 (1 H, s), 9.24 (1 H, dd, J = 4.3, 1.8 Hz), 8.63 (1 H, dd, J = 8.4, 1.8 Hz), 8.46 (1 H, dd, J = 8.2, 1.5 Hz), 8.38 (1 H, dd, J = 7.4, 1.5 Hz), 8.07 (1 H, s), 7.91–7.71 (4 H, m), 7.53 (2 H, dt, J = 8.6, 1.8 Hz), 7.37 (2 H, t, J = 7.9 Hz), 7.27–7.15 (1 H, m), 7.07–6.95 (2 H, m). 13C NMR (101 MHz, DMSO-d6) δ 175.48, 151.87, 149.54, 142.45, 140.51, 138.36, 136.59, 135.81, 133.53, 132.47, 130.62, 128.46, 128.16, 127.44, 125.31, 125.10, 124.78, 122.54, 121.40. ESI-MS: Calculated [M + H]+: 463.089, Found [M + H]+: 463.089; HPLC-PDA: λ 254 nm, MeCN: MeOH (1:1), Rt: 2.89 min, 99.97%. ( E )−4-{[2-((2-Chlorophenyl)carbamothioyl)hydrazono]methyl}phenyl quinoline-8-sulfonate (5b) White solid. Yield: 80%. Mp: 180–182 °C. FTIR (cm− 1) 3268, 3152 (N-H), 2984 (Ar. C–H), 1541 (C = N), 1184 (C = S). 1H NMR (400 MHz, DMSO-d6) δ H 12.00 (1 H, s), 10.07 (1 H, s), 9.24 (1 H, dd, J = 4.2, 1.8 Hz), 8.63 (1 H, dd, J = 8.4, 1.8 Hz), 8.46 (1 H, dd, J = 8.3, 1.5 Hz), 8.38 (1 H, dd, J = 7.4, 1.4 Hz), 8.07 (1 H, s), 7.89–7.70 (4 H, m), 7.62 (1 H, dd, J = 7.8, 1.8 Hz), 7.54 (1 H, dd, J = 7.9, 1.6 Hz), 7.35 (2 H, dtd, J = 25.0, 7.6, 1.7 Hz), 7.09–6.94 (2 H, m). 13C NMR (101 MHz, DMSO-d6) δ 177.38, 152.95, 150.66, 143.52, 141.68, 137.66, 137.00, 136.89, 134.59, 133.51, 131.71, 131.47, 130.65, 129.77, 129.46, 129.23, 128.44, 127.63, 126.18, 123.61, 122.56. ESI-MS: Calculated [M + H]+: 497.051, Found [M + H]+: 497.050; HPLC-PDA: λ 254 nm, MeCN: MeOH (1:1), Rt: 3 min, 99.97%. ( E )−4-{[2-((2-Fluorophenyl)carbamothioyl)hydrazono]methyl}phenyl quinoline-8-sulfonate (5c) Off-white solid. Yield: 79%. Mp: 116–118 °C. FTIR (cm− 1) 3408, 3291, 3106 (N-H), 2955 (Ar. C–H), 1525 (C=N), 1134 (C=S). 1H NMR (400 MHz, DMSO-d6) δ H 12.00 (1 H, s), 9.96 (1 H, s), 9.24 (1 H, dd, J = 4.2, 1.8 Hz), 8.63 (1 H, dd, J = 8.4, 1.8 Hz), 8.46 (1 H, dd, J = 8.2, 1.5 Hz), 8.38 (1 H, dd, J = 7.4, 1.5 Hz), 8.06 (1 H, s), 7.89–7.70 (4 H, m), 7.47 (1 H, td, J = 7.9, 1.8 Hz), 7.27 (3 H, ddtd, J = 30.5, 15.1, 7.9, 1.6 Hz), 7.07–6.95 (2 H, m). 13C NMR (101 MHz, DMSO-d6) δ 177.92, 159.09, 156.63, 152.94, 150.65, 143.52, 141.74, 137.66, 136.89, 134.61, 133.54, 131.69, 130.85, 129.48, 129.23, 128.79, 128.71, 127.58, 127.46, 126.18, 124.50, 124.47, 123.61, 122.50, 116.26, 116.06. ESI-MS: Calculated [M + H]+: 481.080, Found [M + H]+: 481.080; HPLC-PDA: λ 254 nm, MeCN: MeOH (1:1), Rt: 2.87 min, 100%. ( E )−4-{[2-(Cyclohexylcarbamothioyl)hydrazono]methyl}phenyl quinoline-8-sulfonate (5d) White solid. Yield: 71%. Mp: 154–156 °C. FTIR (cm− 1) 3356, 3285, 3144 (N–H), 2925 (Ar. C–H), 1521 (C=N), 1139 (C=S). 1H NMR (400 MHz, DMSO-d6) δ H 11.43 (1 H, s), 9.25 (1 H, dd, J = 4.2, 1.8 Hz), 8.64 (1 H, dd, J = 8.4, 1.8 Hz), 8.47 (1 H, dd, J = 8.3, 1.5 Hz), 8.37 (1 H, dd, J = 7.4, 1.5 Hz), 8.06–7.92 (2 H, m), 7.83 (1 H, dd, J = 8.4, 4.2 Hz), 7.79–7.68 (3 H, m), 7.06–6.95 (2 H, m), 4.18 (1 H, dtd, J = 11.0, 7.5, 4.2 Hz), 1.84 (2 H, dd, J = 12.2, 3.9 Hz), 1.72 (2 H, dt, J = 13.1, 3.4 Hz), 1.66–1.54 (1 H, m), 1.39 (2 H, qd, J = 12.0, 3.1 Hz), 1.33–1.19 (2 H, m), 1.11 (1 H, ddd, J = 15.8, 7.9, 3.4 Hz). 13C NMR (101 MHz, DMSO-d6) δ 176.18, 152.95, 150.46, 143.51, 140.87, 137.67, 136.89, 134.60, 133.62, 131.67, 129.24, 129.22, 126.17, 123.62, 122.50, 53.17, 32.23, 25.61, 25.42. ESI-MS: Calculated [M + H]+: 469.136, Found [M + H]+: 469.136; HPLC-PDA: λ 254 nm, MeCN: MeOH (1:1), Rt: 3.1 min, 99.98%. ( E )−4-{[2-((4-Fluorophenyl)carbamothioyl)hydrazono]methyl}phenyl quinoline-8-sulfonate (5e) White solid. Yield: 86%. Mp: 218–220 °C. FTIR (cm− 1) 3246 (N-H), 3062 (Ar. C–H), 1522 (C=N), 1132 (C=S). 1H NMR (400 MHz, DMSO-d6) δ H 11.88 (1 H, s), 10.08 (1 H, s), 9.24 (1 H, dd, J = 4.2, 1.8 Hz), 8.63 (1 H, dd, J = 8.4, 1.8 Hz), 8.46 (1 H, dd, J = 8.2, 1.5 Hz), 8.38 (1 H, dd, J = 7.5, 1.5 Hz), 8.06 (1 H, s), 7.88–7.70 (4 H, m), 7.57–7.44 (2 H, m), 7.25–7.13 (2 H, m), 7.05–6.92 (2 H, m). 13C NMR (101 MHz, DMSO-d6) δ 175.84, 160.29, 157.88, 151.88, 149.56, 142.45, 140.61, 136.60, 135.83, 134.73, 134.70, 133.54, 132.46, 130.62, 128.46, 128.17, 127.61, 127.53, 125.11, 122.55, 121.40, 114.22, 114.00. ESI-MS: Calculated [M + H]+: 481.080, Found [M + H]+: 481.080; HPLC-PDA: λ 254 nm, MeCN: MeOH (1:1), Rt: 2.87 min, 99.92%. ( E )−4-{[2-((4-Chlorobenzyl)carbamothioyl)hydrazono]methyl}phenyl quinoline-8-sulfonate (5f) Off-white solid. Yield: 95%. Mp: 227–229 °C. FTIR (cm− 1) 3279, 3158 (N–H), 2984 (Ar. C–H), 1535 (C=N), 1189 (C=S).1H NMR (400 MHz, DMSO-d6) δ H 11.67 (1 H, s), 9.24 (1 H, dd, J = 4.3, 1.8 Hz), 9.11 (1 H, t, J = 6.3 Hz), 8.63 (1 H, dd, J = 8.4, 1.8 Hz), 8.46 (1 H, dd, J = 8.3, 1.5 Hz), 8.37 (1 H, dd, J = 7.4, 1.4 Hz), 8.00 (1 H, s), 7.82 (1 H, dd, J = 8.4, 4.2 Hz), 7.76 (3 H, dd, J = 8.4, 6.1 Hz), 7.46–7.26 (4 H, m), 7.08–6.92 (2 H, m), 4.80 (2 H, d, J = 6.2 Hz). 13C NMR (101 MHz, DMSO-d6) δ 178.16, 152.93, 150.50, 143.51, 141.07, 138.89, 137.66, 136.88, 134.61, 133.70, 131.70, 131.67, 129.52, 129.22, 129.18, 128.57, 126.16, 123.60, 122.49, 46.36. ESI-MS: Calculated [M + H]+: 511.067, Found [M + H]+: 511.066; HPLC-PDA: λ 254 nm, MeCN: MeOH (1:1), Rt: 3.02 min, 99.92%. (E)−4-{[2-((2,3-Dichlorophenyl)carbamothioyl)hydrazono]methyl}phenyl quinoline-8-sulfonate (5 g) White solid. Yield: 99%. Mp: 216–218 °C. FTIR (cm− 1) 3276, 3151 (N–H), 2980 (Ar. C–H), 1538 (C=N), 1186 (C=S). 1H NMR (400 MHz, DMSO-d6) δ H 12.09 (1 H, s), 10.17 (1 H, s), 9.25 (1 H, dd, J = 4.2, 1.8 Hz), 8.63 (1 H, dd, J = 8.4, 1.8 Hz), 8.46 (1 H, dd, J = 8.2, 1.5 Hz), 8.39 (1 H, dd, J = 7.5, 1.5 Hz), 8.08 (1 H, s), 7.88–7.72 (4 H, m), 7.59 (2 H, d, J = 8.0 Hz), 7.46–7.35 (1 H, m), 7.10–6.96 (2 H, m). 13C NMR (101 MHz, DMSO-d6) δ 177.42, 152.94, 150.71, 143.52, 141.96, 139.15, 137.66, 136.89, 134.59, 133.45, 132.11, 131.70, 130.54, 129.66, 129.50, 129.23, 128.96, 128.10, 126.17, 123.60, 122.56. ESI-MS: Calculated [M + H]+: 531.012, Found [M + H]+: 531.011; HPLC-PDA: λ 254 nm, MeCN: MeOH (1:1), Rt: 3.11 min, 99.61%. (E)−4-{[2-((2,6-Dimethylphenyl)carbamothioyl)hydrazono]methyl}phenyl quinoline-8-sulfonate (5 h) White solid. Yield: 67%. Mp: 223–225 °C. FTIR (cm− 1) 3344, 3113 (N-H), 2966 (Ar. C–H), 1521 (C=N), 1135 (C=S). 1H NMR (400 MHz, DMSO-d6) δ H 11.78 (1 H, s), 9.86 (1 H, s), 9.24 (1 H, dd, J = 4.2, 1.8 Hz), 8.63 (1 H, dd, J = 8.4, 1.8 Hz), 8.46 (1 H, dd, J = 8.3, 1.5 Hz), 8.38 (1 H, dd, J = 7.4, 1.5 Hz), 8.04 (1 H, s), 7.91–7.70 (4 H, m), 7.16–7.07 (3 H, m), 7.04–6.92 (2 H, m), 2.16 (6 H, s). 13C NMR (101 MHz, DMSO-d6) δ 177.31, 152.93, 150.47, 143.53, 140.86, 137.66, 137.52, 136.88, 136.85, 134.60, 133.83, 131.72, 129.40, 129.23, 128.03, 127.37, 126.19, 123.60, 122.43, 18.45. ESI-MS: Calculated [M + H]+: 491.121, Found [M + H]+: 491.121; HPLC-PDA: λ 254 nm, MeCN: MeOH (1:1), Rt: 2.91 min, 99.75%. ( E )−4-{[2-((4-Bromophenyl)carbamothioyl)hydrazono]methyl}phenyl quinoline-8-sulfonate (5i) Off-white solid. Yield: 75%. Mp: 234–235 °C. FTIR (cm− 1) 3328, 3115 (N–H), 2973 (Ar. C–H), 1534 (C=N), 1135 (C=S). 1H NMR (400 MHz, DMSO-d6) δ H 11.96 (1 H, s), 10.11 (1 H, s), 9.25 (1 H, dd, J = 4.2, 1.8 Hz), 8.72–8.56 (1 H, m), 8.46 (1 H, d, J = 8.2 Hz), 8.45–8.33 (1 H, m), 8.08 (1 H, s), 7.92–7.73 (4 H, m), 7.55 (4 H, s), 7.02 (2 H, d, J = 8.4 Hz). 13C NMR (101 MHz, DMSO-d6) δ 176.45, 152.94, 150.69, 143.52, 141.97, 138.86, 137.66, 136.89, 134.61, 133.45, 131.69, 131.34, 129.59, 129.23, 128.28, 126.17, 123.61, 122.50, 118.10. ESI-MS: Calculated [M + H]+: 541.000, Found [M + H]+: 541.000; HPLC-PDA: λ 254 nm, MeCN: MeOH (1:1), Rt: 3.04 min, 99.86%. ( E )−4-{[2-(Benzylcarbamothioyl)hydrazono]methyl}phenyl quinoline-8-sulfonate (5j) White solid. Yield: 57%. Mp: 130–132 °C. FTIR (cm− 1) 3330, 3116 (N–H), 2958 (Ar. C–H), 1527 (C=N), 1124 (C=S). 1H NMR (400 MHz, DMSO-d6) δ H 11.63 (1 H, s), 9.23 (1 H, dd, J = 4.2, 1.8 Hz), 9.08 (1 H, t, J = 6.3 Hz), 8.62 (1 H, dd, J = 8.4, 1.8 Hz), 8.45 (1 H, dd, J = 8.3, 1.5 Hz), 8.36 (1 H, dd, J = 7.5, 1.5 Hz), 7.99 (1 H, s), 7.81 (1 H, dd, J = 8.4, 4.2 Hz), 7.75 (3 H, dd, J = 8.4, 6.5 Hz), 7.37–7.28 (4 H, m), 7.23 (1 H, dq, J = 7.7, 2.8 Hz), 7.03–6.92 (2 H, m), 4.82 (2 H, d, J = 6.2 Hz). 13C NMR (101 MHz, DMSO-d6) δ 178.12, 152.94, 150.46, 143.51, 140.93, 139.82, 137.66, 136.89, 134.61, 133.73, 131.66, 129.22, 129.17, 128.61, 127.62, 127.17, 126.17, 123.60, 122.49, 47.01. ESI-MS: Calculated [M + H]+: 477.105, Found [M + H]+: 477.105; HPLC-PDA: λ 254 nm, MeCN: MeOH (1:1), Rt: 2.92 min, 99.83%. ( E )−4-{[2-((3-Methoxyphenyl)carbamothioyl)hydrazono]methyl}phenyl quinoline-8-sulfonate (5k) Off-white solid. Yield: 93%. Mp: 177–179 °C. FTIR (cm− 1) 3302 (N–H), 2938 (Ar. C–H), 1549 (C=N), 1135 (C=S). 1H NMR (400 MHz, DMSO-d6) δ H 11.88 (1 H, s), 10.04 (1 H, s), 9.25 (1 H, dd, J = 4.2, 1.8 Hz), 8.63 (1 H, dd, J = 8.4, 1.8 Hz), 8.46 (1 H, dd, J = 8.3, 1.5 Hz), 8.39 (1 H, dd, J = 7.5, 1.5 Hz), 8.08 (1 H, s), 7.94–7.68 (4 H, m), 7.35–7.23 (2 H, m), 7.23–7.10 (1 H, m), 7.11–6.96 (2 H, m), 6.88–6.72 (1 H, m), 3.77 (3 H, s). 13C NMR (101 MHz, DMSO-d6) δ 176.28, 159.46, 152.94, 150.65, 143.53, 141.68, 140.53, 137.66, 136.89, 134.60, 133.50, 131.70, 129.57, 129.23, 129.21, 126.17, 123.61, 122.49, 118.32, 111.80, 111.29, 55.62. ESI-MS: Calculated [M + H]+: 493.100, Found [M + H]+: 493.100; HPLC-PDA: λ 254 nm, MeCN: MeOH (1:1), Rt: 2.88 min, 99.89%. ( E )−4-{[2-(Methylcarbamothioyl)hydrazono]methyl}phenyl quinoline-8-sulfonate (5 L) Pale yellow solid. Yield: 58%. Mp: 199–201 °C. FTIR (cm− 1) 3358, 3131 (N–H), 2979 (Ar. C–H), 1551 (C=N), 1166 (C=S). 1H NMR (400 MHz, DMSO-d6) δ H 11.52 (1 H, s), 9.25 (1 H, dd, J = 4.3, 1.8 Hz), 8.64 (1 H, dd, J = 8.4, 1.8 Hz), 8.55–8.43 (2 H, m), 8.38 (1 H, dd, J = 7.4, 1.5 Hz), 7.96 (1 H, s), 7.83 (1 H, dd, J = 8.4, 4.2 Hz), 7.80–7.69 (3 H, m), 7.06–6.95 (2 H, m), 3.00 (3 H, d, J = 4.6 Hz). 13C NMR (101 MHz, DMSO-d6) δ 178.23, 152.94, 150.38, 143.52, 140.37, 137.66, 136.87, 134.60, 133.83, 131.70, 129.23, 129.03, 126.17, 123.61, 122.50, 31.26. ESI-MS: Calculated [M + H]+: 401.074, Found [M + H]+: 401.074; HPLC-PDA: λ 254 nm, MeCN: MeOH (1:1), Rt: 2.85 min, 99.91%. (E)−4-{[2-((2,4-Dimethylphenyl)carbamothioyl)hydrazono]methyl}phenyl quinoline-8-sulfonate (5 m) White solid. Yield: 33%. Mp: 239–241 °C. FTIR (cm− 1) 3144 (N–H), 2983 (Ar. C–H), 1532 (C=N), 1137 (C=S). 1H NMR (400 MHz, DMSO-d6) δ H 11.76 (1 H, s), 9.87 (1 H, s), 9.23 (1 H, dd, J = 4.2, 1.8 Hz), 8.63 (1 H, dd, J = 8.4, 1.8 Hz), 8.46 (1 H, dd, J = 8.2, 1.5 Hz), 8.37 (1 H, dd, J = 7.4, 1.5 Hz), 8.02 (1 H, s), 7.87–7.70 (4 H, m), 7.12–7.03 (2 H, m), 7.02–6.91 (3 H, m), 2.28 (3 H, s), 2.14 (3 H, s). 13C NMR (101 MHz, DMSO-d6) δ 177.54, 152.94, 150.49, 143.52, 140.99, 137.67, 136.88, 136.32, 135.89, 135.68, 134.60, 133.75, 131.70, 131.06, 129.40, 129.23, 129.02, 126.92, 126.18, 123.61, 122.45, 21.08, 18.17. ESI-MS: Calculated [M + H]+: 491.121, Found [M + H]+: 491.121; HPLC-PDA: λ 254 nm, MeCN: MeOH (1:1), Rt: 2.95 min, 99.55%. ( E )−4-{[2-( o -Tolylcarbamothioyl)hydrazono]methyl}phenyl quinoline-8-sulfonate (5n) Light brown solid. Yield: 67%. Mp: 192–194 °C. FTIR (cm− 1) 3336, 3163 (N–H), 2985 (Ar. C–H), 1527 (C=N), 1187 (C=S). 1H NMR (400 MHz, DMSO-d6) δ H 11.80 (1 H, s), 9.95 (1 H, s), 9.23 (1 H, dd, J = 4.3, 1.8 Hz), 8.63 (1 H, dd, J = 8.4, 1.8 Hz), 8.46 (1 H, dd, J = 8.3, 1.5 Hz), 8.37 (1 H, dd, J = 7.4, 1.4 Hz), 8.04 (1 H, s), 7.87–7.79 (3 H, m), 7.76 (1 H, dd, J = 8.2, 7.4 Hz), 7.31–7.16 (4 H, m), 7.02–6.92 (2 H, m), 2.19 (3 H, s). 13C NMR (101 MHz, DMSO-d6) δ 177.41, 152.94, 150.52, 143.52, 141.10, 138.48, 137.67, 136.89, 136.03, 134.60, 133.72, 131.70, 130.51, 129.42, 129.26, 129.23, 127.25, 126.38, 126.19, 123.61, 122.46, 18.23. ESI-MS: Calculated [M + H]+: 477.105, Found [M + H]+: 477.105; HPLC-PDA: λ 254 nm, MeCN: MeOH (1:1), Rt: 2.89 min, 99.96%. ( E )−4-{[2-(Sec-butylcarbamothioyl)hydrazono]methyl}phenyl quinoline-8-sulfonate (5o) Off-white solid. Yield: 66%. Mp: 202–204 °C. FTIR (cm− 1) 3353, 3165 (N–H), 2951 (Ar. C–H), 1534 (C=N), 1186 (C=S). 1H NMR (400 MHz, DMSO-d6) δ H 11.45 (1 H, s), 9.24 (1 H, dd, J = 4.2, 1.8 Hz), 8.64 (1 H, dd, J = 8.4, 1.8 Hz), 8.53–8.42 (2 H, m), 8.37 (1 H, dd, J = 7.4, 1.4 Hz), 7.96 (1 H, s), 7.82 (1 H, dd, J = 8.4, 4.2 Hz), 7.79–7.70 (3 H, m), 7.05–6.96 (2 H, m), 3.42–3.31 (2 H, m), 2.00 (1 H, dq, J = 13.6, 6.8 Hz), 0.86 (6 H, d, J = 6.8 Hz). 13C NMR (101 MHz, DMSO-d6) δ 177.74, 152.95, 150.42, 143.52, 140.57, 137.67, 136.89, 134.60, 133.77, 131.69, 129.24, 129.10, 126.18, 123.62, 122.51, 51.26, 28.27, 20.56. ESI-MS: Calculated [M + H]+: 443.121, Found [M + H]+: 443.121; HPLC-PDA: λ 254 nm, MeCN: MeOH (1:1), Rt: 2.98 min, 99.88%. ( E )−4-{[2-((4-Chlorophenyl)carbamothioyl)hydrazono]methyl}phenyl quinoline-8-sulfonate (5p) Off-white solid. Yield: 73%. Mp: 237–239 °C. FTIR (cm− 1) 3328, 3127 (N–H), 2978 (Ar. C–H), 1533 (C=N), 1188 (C = S). 1H NMR (400 MHz, DMSO-d6) δ H) 11.93 (1 H, s), 10.11 (1 H, s), 9.24 (1 H, dd, J = 4.2, 1.8 Hz), 8.63 (1 H, dd, J = 8.4, 1.8 Hz), 8.46 (1 H, dd, J = 8.3, 1.5 Hz), 8.37 (1 H, dd, J = 7.5, 1.5 Hz), 8.07 (1 H, s), 7.88–7.80 (3 H, m), 7.76 (1 H, t, J = 7.8 Hz), 7.64–7.54 (2 H, m), 7.49–7.37 (2 H, m), 7.07–6.95 (2 H, m). 13C NMR (101 MHz, DMSO-d6) δ 175.45, 151.88, 149.60, 142.44, 140.85, 137.35, 136.60, 135.82, 133.54, 132.38, 130.61, 128.76, 128.50, 128.16, 127.33, 126.90, 125.10, 122.54, 121.41. ESI-MS: Calculated [M + H]+: 497.051, Found [M + H]+: 497.050; HPLC-PDA: λ 254 nm, MeCN: MeOH (1:1), Rt: 2.99 min, 99.87%. ( E )−4-{[2-((4-Fluorobenzyl)carbamothioyl)hydrazono]methyl}phenyl quinoline-8-sulfonate (5q) White solid. Yield: 87%. Mp: 154–156 °C. FTIR (cm− 1) 3331, 3115 (N–H), 2984 (Ar. C–H), 1544 (C=N), 1125 (C=S). 1H NMR (400 MHz, DMSO-d6) δ H 11.64 (1 H, s), 9.23 (1 H, dd, J = 4.2, 1.8 Hz), 9.08 (1 H, t, J = 6.3 Hz), 8.63 (1 H, dd, J = 8.4, 1.8 Hz), 8.45 (1 H, dd, J = 8.3, 1.5 Hz), 8.36 (1 H, dd, J = 7.5, 1.5 Hz), 7.99 (1 H, s), 7.81 (1 H, dd, J = 8.4, 4.2 Hz), 7.79–7.70 (3 H, m), 7.43–7.30 (2 H, m), 7.23–7.07 (2 H, m), 7.06–6.94 (2 H, m), 4.79 (2 H, d, J = 6.2 Hz). 13C NMR (101 MHz, DMSO-d6) δ 178.06, 162.81, 160.40, 152.94, 150.48, 143.51, 141.02, 137.67, 136.89, 136.01, 135.99, 134.61, 133.70, 131.66, 129.69, 129.61, 129.22, 129.17, 126.17, 123.61, 122.49, 115.43, 115.22, 46.29. ESI-MS: Calculated [M + H]+: 495.096, Found [M + H]+: 495.096; HPLC-PDA: λ 254 nm, MeCN: MeOH (1:1), Rt: 2.9 min, 99.90%. ( E )−4-[(2-Carbamothioylhydrazono)methyl]phenyl quinoline-8-sulfonate (5r) White solid. Yield: 91%. Mp: 230–232 °C. FTIR (cm− 1) 3379, 3259, 3157 (N–H), 3019 (Ar. C–H), 1562 (C=N), 1190 (C=S). 1H NMR (400 MHz, DMSO-d6) δ H 11.47 (1 H, s), 9.25 (1 H, dd, J = 4.2, 1.8 Hz), 8.64 (1 H, dd, J = 8.4, 1.8 Hz), 8.47 (1 H, dd, J = 8.2, 1.4 Hz), 8.38 (1 H, dd, J = 7.5, 1.5 Hz), 8.24 (1 H, s), 8.01 (1 H, s), 7.97 (1 H, s), 7.83 (1 H, dd, J = 8.3, 4.2 Hz), 7.80–7.72 (3 H, m), 7.07–6.95 (2 H, m). 13C NMR (101 MHz, DMSO-d6) δ 178.54, 152.94, 150.46, 143.51, 140.98, 137.65, 136.87, 134.57, 133.73, 131.71, 129.22, 129.18, 126.16, 123.60, 122.50. ESI-MS: Calculated [M + H]+: 387.058, Found [M + H]+: 387.058; HPLC-PDA: λ 254 nm, MeCN: MeOH (1:1), Rt: 2.76 min, 99.93%. Inhibition assays Activity and inhibition test for ache and BChE Both acetylcholine iodide (AChI) and butyrylcholine iodide (BChI) were employed as substrates for enzymatic hydrolysis reactions, with 5,5′-dithiobis(2-nitrobenzoic acid) (DTNB) used as a chromogenic reagent to detect the activities of AChE and BChE. The assay was carried out as follows: 1 mL of 1.0 M Tris-HCl buffer (pH 8.0) was mixed with 10 µL of the test sample (prepared in deionized water). To this mixture, 50 µL of AChE or BChE enzyme solution was added, and the reaction mixture was incubated at room temperature for 10 min. Following incubation, 50 µL of DTNB solution (0.5 mM) was added, and the enzymatic reaction was initiated by the addition of 50 µL of either AChI or BChI (10 mM). The hydrolysis of the substrates was monitored spectrophotometrically by measuring the absorbance at 412 nm, corresponding to the formation of the yellow-colored 5-thio-2-nitrobenzoate anion. This colorimetric change results from the reaction of DTNB with thiocholine, which is released upon enzymatic hydrolysis of AChI or BChI. Inhibitory activities were assessed by determining the IC₅₀ and Ki values for each compound showing inhibition. For compounds demonstrating inhibitory effects, activity (%)-[I] plots were constructed to calculate the IC₅₀ values and the concentrations of inhibitor required to achieve 50% enzyme inhibition. The enzymes used in this study were: BChE from equine serum (C7512) and AChE from Electrophorus electricus (electric eel, C3389), both purchased from Sigma-Aldrich38,39. We started this investigation with an IC50 inhibition analysis. The inhibitor concentration that reduces enzyme activity by half is known as the IC50. Three concentrations were chosen from this paper to start our Ki investigation, and we also examined three distinct inhibitor concentrations using a control. We plotted the Ki graph after determining 1/S and 1/V, then we determined the Ki value according to the graph type (competitive or non-competitive). The Ki’s mean and standard deviation were determined and entered into the Table 1. Study of MAO-A inhibition The in-vitro fluorometric method was used to evaluate each newly generated substance’s inhibitory activity against hMAO-A. In a horseradish peroxidase coupling reaction, the oxired reagent (10-acetyl-3,7-dihydroxyphenoxazine) detects H2O2, resulting from the oxidative deamination of tyramine, being utilized as MAO substrate. Firstly, each compound’s concentrations of 10–3 and 10–4 M were studied. In the second step, substances that demonstrated inhibitory activity at a concentration of 10−5–10−9 M more than 50% were subjected to additional analysis to find out the IC50 value for hMAO-A isoform as reported in previous studies24. The enzymes were purchased from Sigma Aldrich. (M7316-Monoamine Oxidase A human and M7441- Monoamine Oxidase A human)39. Computational methods Molecular docking studies For molecular docking studies the crystal structures of hMAO (PDB id: 2z5x at 2.20 Å resolution)40 [, AChE (PDB id: 4m0e at 2.0 Å resolution)41 and BChE (PDB id: 4bds at 2.10 Å resolution)42 were downloaded from the PDB. Method validation was ascertained by re-docking the co-crystalized ligand in to the binding site, each time the docking results revealed the docked ligand orientation to be the same as seen in the original crystal structure. For each compound docked, a total of ten docking solutions were generated, each was individually analyzed, finally the one with most favorable binding energy as indicated by the HYDE scoring function of the BioSolveIT’s LeadIT (2.3.2, 2017) software (www.biosolveit.de/LeadIT)43 was selected for detailed analysis of docking interactions. Default docking settings (ligand binding is driven by enthalpy and entropy, hybrid approach) were used. Maximum number of solutions per iteration and maximum number of solutions per fragmentation were also set to default. Molecular dynamics (MD) simulation studies Schrödinger Maestro 2024.4 program and Desmond Molecular Dynamics44 software was utilized for the MD studies of 5c-MAO-A, 5e-AChE, and 5 g-BChE complexes. The best-docked pose complexes of compounds 5c, 5e, and 5 g with MAO-A, AChE, and BChE, respectively, were used as the initial reference structures. In protein preparation, first, the sole respective proteins were processed with the Protein Preparation Wizard of the program for pre-processing and refinement of the structure, then the refined protein structures were complexed with their respective compounds, and subsequently, the complexes were re-run on the protein preparation wizard by keeping all initial parameters the same, except bond order assignment using CCD was kept to missing only for the complexes. The details for the protein preparation and molecular dynamics simulation workflow are mentioned in the supplementary section. An orthorhombic box shape was opted for solvation with pre-defined TIP3P solvent model for water with 10 Å x 10 Å x 10 Å buffer dimensions through the system builder module. Ions placement was done using default values calculated by the software for each respective complex, additionally, to simulate physiological (natural) conditions NaCl (0.15 M) was also included. In the MD simulation was run for 100ns (nanoseconds), trajectory was recorded at every 100ps (picoseconds), resulting in approximately 1000 frames. Default relaxation protocol, NPT ensemble at 1.01325 bar pressure and 300 K temperature using Martyna-Tobias-Klein barostat and Nosé-Hoover chain thermostat settings was used. Conclusion A novel series of 4-phenyl-quinoline-8-sulfonate-based thiosemicarbazones (5a–r) was synthesized and evaluated for inhibitory activity against AChE, BChE, and MAO-A. The SAR analysis revealed that both the nature and position of aromatic substituents significantly influenced enzyme inhibition. Among the series, compound 5c, bearing 2-fluorophenyl moiety, exhibited the most potent multi-target activity with IC50 values of 78.07 ± 3.14 µM for AChE, 22.63 ± 2.81 µM for BChE, and 0.84 ± 0.01 µM for MAO-A, along with the lowest Ki values across all targets. The enhanced activity of 5c is attributed to the presence of an o-fluoro substituent, likely enhancing binding interactions within the enzyme active sites. Notably, several derivatives demonstrated stronger inhibition of BChE relative to AChE, supporting the therapeutic relevance of BChE inhibition in the advanced stages of (AD). Furthermore, the noticeable MAO-A inhibitory activity was observed, particularly 5c, which suppressed clorgyline, underscore the dual-target potential of these compounds. The study demonstrates that strategic substitutions significantly influence pharmacological profiles, with compound 5c emerging as a promising scaffold for designing multifunctional therapeutic targeting key enzymes implicated in (AD). Supplementary Information Below is the link to the electronic supplementary material. Supplementary Material 1 Supplementary Material 1